智能终端>文传商讯

Intelligent Terminal

Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity

作者: CN-INFO   责任编辑:文传商讯 2021-03-02 09:48:00
来源:文传商讯关键字:null

The research agreement builds upon the successful relationship between Boehringer Ingelheim and Gubra and expands Boehringer Ingelheim’s research into approaches with first in class potential for the treatment of obesity
Obesity is a complex cardiometabolic disease with growing global prevalence and limited treatment options that are not sufficiently effective or are associated with adverse events

INGELHEIM, Germany & HØRSHOLM, Denmark--()--Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. The companies share the goal of providing new obesity therapies with increased tolerability that support greater weight loss than current therapy options.

“This marks the third joint research program between Boehringer Ingelheim and Gubra in the area of obesity since 2017,” said Søren Tullin, Ph.D., Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. “We’re delighted to expand our established working relationship and proven track record with Gubra to uncover next-generation anti-obesity treatments. This latest research agreement further strengthens and complements Boehringer Ingelheim’s cardiometabolic portfolio. We are committed to becoming a leader in the obesity space and to providing new therapy options to help people with high unmet medical needs.”

Obesity is a complex chronic disease that requires long-term management. It is among the leading risk factors for several cardio-metabolic diseases, such as heart disease, ischemic stroke, liver diseases incl. NASH and type 2 diabetes, as well as for a number of cancers.i The global prevalence of obesity has increased dramatically over the last decade and nearly tripled between 1975 and 2016,ii affecting around 650 million adults worldwide today.ii It is projected that by 2030, close to half of the U.S. population will have obesity.iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events.

“We are particularly pleased about this third collaboration with Boehringer Ingelheim,” said Henrik Blou, CEO of Gubra. “Over the past four years our two companies have built a strong drug discovery relationship. In this third collaboration, Gubra is responsible for the early discovery of peptides – now applying our proprietary target and drug discovery platform streaMLine. After initial maturation, projects are handed over for further development to Boehringer Ingelheim. This approach, we believe, has the potential to take obesity treatment to the next level for the benefit of patients around the world.”

Under the terms of the agreement, Gubra is primarily responsible for early research activities. Boehringer Ingelheim will advance the programs further and bring promising candidates into non-clinical and clinical development. Financial terms of the new agreement are not disclosed.

Please click on the following link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/research-collaboration-gubra-obesity-treatment

Contacts

Boehringer Ingelheim
Dr. Birgit Leimer
Media Contact
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77- 173316
press@boehringer-ingelheim.com

Linda Ruckel
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
press@boehringer-ingelheim.com

Gubra
Henrik Blou
CEO
P.: +45 2861 6845
hbl@gubra.dk

CBI 友情链接: 至顶网 |  腾讯科技 |  凤凰科技 |  商业伙伴 |  移动信息化 |  企业网 |  中国软件网 |  CIO时代网 |  更多>>

CBI集团介绍 |  联系我们 |  CBINEWS刊例 |  版权声明  

版权所有:电脑商情信息服务集团 北京三人行广告有限公司

地址:北京海淀区学院南路68号吉安大厦B座308联系电话:(010)62178877

商务、内容合作QQ:2291221 联系电话:13391790444 詹老师

ICP证:川B2-20070068-5 川预审H8VZ-RBP6-X228-T60Z号 北京市公安局海淀分局备案编号:1101083710

声明:本媒体部分图片、文章来源于网络,版权归原作者所有,我司致力于保护作者版权,如有侵权,请与我司联系删除